Rabbit Polyclonal ENT1 Antibody

+ +

•  

   
     All lanes : Anti-ENT1 Antibody (C-term) at 1:1000 dilution Lane 1: Mouse heart lysate Lane 2: Mouse liver lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 50 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     All lanes : Anti-ENT1 Antibody (C-term) at 1:1000 dilution Lane 1: Human brain lysate Lane 2: Human breast lysate Lane 3: Human placenta lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 50 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Western blot analysis of lysate from human heart tissue lysate, using ENT1(Slc29a1) Antibody (C-term)(Cat.  #P34585).  P34585 was diluted at 1:1000.  A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.    

•  

   
     Overlay histogram showing HepG2 cells stained with P34585(green line).  The cells were fixed with 2% paraformaldehyde 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34585,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(1583138) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     Overlay histogram showing HepG2 cells stained with P34585(green line).  The cells were fixed with 2% paraformaldehyde 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34585,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(1583138) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     Immunohistochemical analysis of paraffin-embedded human brain tissue using P34585 performed on the Leica® BOND RXm. Samples were incubated with primary antibody(1/500) for 1 hours at room temperature.  A undiluted biotinylated CRF Anti-Polyvalent HRP Polymer antibody was used as the secondary antibody.    

**Background of ENT1 Antibody**

The ENT1 (Equilibrative Nucleoside Transporter 1) antibody is a tool used to detect and study the ENT1 protein, a member of the solute carrier 29 (SLC29) family. ENT1 facilitates the bidirectional transport of nucleosides and nucleoside analogs across cell membranes, playing a critical role in cellular nucleotide salvage pathways and the uptake of therapeutic drugs like chemotherapy agents (e.g., gemcitabine). It is widely expressed in tissues, including the brain, heart, and skeletal muscle, and is implicated in physiological processes such as adenosine signaling, which influences cardiovascular and neurological functions.

ENT1 has garnered attention in cancer research due to its role in drug resistance. Reduced ENT1 expression in tumors is linked to decreased intracellular accumulation of nucleoside-based chemotherapeutics, contributing to treatment failure. The ENT1 antibody enables researchers to assess protein expression levels and localization in cells or tissues, aiding studies on mechanisms of drug resistance, tissue-specific nucleoside regulation, and disease biomarkers.

Commercially available ENT1 antibodies are typically validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Their specificity and reliability are critical for accurate experimental outcomes. Research using ENT1 antibodies continues to advance understanding of nucleoside transport dynamics, with implications for developing targeted therapies and personalized treatment strategies in oncology and other fields.